SRX Global Inc. completed a secured financing transaction with CERo Therapeutics Holdings, Inc., issuing a Consolidated Senior Secured Promissory Note aggregating $5,666,108.77 to consolidate previous convertible notes. The agreement allows for additional advances up to $6,000,000, bringing the maximum loan facility to $11,666,108.77. An initial advance of $775,665.00 was funded on August 27, 2026, with monthly funding scheduled thereafter based on CERO's budget. The debt bears interest at 10% per annum and matures on October 15, 2026, secured by CERO’s subsidiary stock and assets. SRX Global Inc. operates as an AI-enabled investment platform focused on generating shareholder value through strategic investments in operating companies.

SRX Global Inc. entered into a Securities Purchase Agreement on August 27, 2026, selling 3,579 shares of Series C convertible preferred stock to accredited investors for $2,862,500. The purchase price was satisfied by the assignment of Convertible Grid Promissory Notes from CERO Therapeutics Holdings with an aggregate principal amount of $2,812,500. Each share has a stated value of $1,000 and converts at a fixed price of $2.1888 per share into common stock. The company also entered a Registration Rights Agreement to register the resale of shares issuable upon conversion and warrant exercise. SRX Global Inc. operates in the biotechnology sector.

SRX Global Inc. reported fiscal third quarter results ended June 30, 2026, with net sales of $3.4 million and a net loss from continuing operations of $4.1 million. The company completed the acquisition of EMJX on June 16, 2026, an AI-enabled digital-asset treasury platform. It declared a one-time cash dividend of $0.05 per share to shareholders of record on July 22, 2026. Net asset value was reported at $62.9 million, or $3.22 per common share, following a one-for-sixty reverse stock split effective July 6, 2026. The company also approved a $10 million share repurchase program and ended the quarter with $36.7 million in cash and no debt outstanding. SRX Global Inc. operates as an investment holding company focused on AI-enabled platforms and strategic assets.

SRX Global Inc. filed an amendment to correct a typographical error in its prior report by clarifying that Carolina Martinez serves as the Chief Financial Officer, not the CEO. The filing also discloses a private placement closing on July 27, 2026, where the company issued 4,340 shares of Series B convertible preferred stock and 284,156 warrants for approximately $3.472 million in cash proceeds. This transaction reflects the final tranche under a Securities Purchase Agreement initiated on March 16, 2026, bringing total aggregate proceeds to approximately $8.0 million. The warrant count was adjusted to account for the company's previously announced 60-for-1 reverse stock split effective July 2, 2026. SRX Global Inc. operates in the healthcare sector.

SRX Global Inc. completed an additional closing of a private placement under a Securities Purchase Agreement dated March 16, 2026. On July 27, 2026, the company issued 4,340 shares of Series B convertible preferred stock and 284,156 warrants to purchase common stock to accredited investors. The transaction generated approximately $3.472 million in aggregate cash proceeds. The warrant count reflects the company's 60-for-1 reverse stock split, which became effective on July 2, 2026. This financing brings total proceeds under the agreement to approximately $8.0 million. SRX Global Inc. operates in the healthcare sector, specifically focusing on digital health solutions and medical technology.